Pros and Cons of Clinical Trials vs. Observational Studies. Beth Devine PCORP Summer Institute July 14, 2015
|
|
- Sophia Fisher
- 6 years ago
- Views:
Transcription
1 Pros and Cons of Clinical Trials vs. Observational Studies Beth Devine PCORP Summer Institute July 14, 2015
2 Outline Randomized Trials Definitions: Pragmatic-explanatory continuum indicator summary (PRECIS) Examples Observational Studies Definitions and types of observational data Advantages and disadvantages of observational data research Good practices in observational data research Examples
3 Learning Objectives Define the RCT continuum Describe appropriate use of pragmatic vs. explanatory trials List and define the major types of observational studies Describe uses, advantages and disadvantages of the major types of observational studies Locate good research practice tools for use when conducting observational studies
4 Part I: RCTs
5 Benefit of RCTs Randomization is the ONLY way to guarantee unbiasedness, particularly as it relates to unknown or unrecorded prognostic factors!
6 Pragmatic-Explanatory Continuum Pragmatic describes trials that help users choose between options for care Explanatory describes trials that test causal research hypotheses Both are randomized Represents a spectrum Impossible to perform a purely pragmatic or purely explanatory trial Reflects judgments made by trialists in study design phase Thorpe. CMAJ. 2009;188(10):E47-E57
7 PRECIS Tool 10 extreme domains Explanatory Pragmatic Participants Restricted Take all comers Interventions Strict instructions Flexible instructions Seasoned practitioners/settings Full range of practitioners/settings Comparator Restricted (placebo) Usual practice Standardized Ordinary attention Follow-up Frequent/extensive No formal F/U; registries Compliance (participant) Direct/immediate/ surrogate Closely monitored/followed Objectively measured; Assessed under usual conditions Unobtrusive Adherence (provider) Closely monitored Unobtrusive Analysis Intent to treat All patients Thorpe. CMAJ. 2009;188(10):E47-E57
8 PRECIS Tool Thorpe. CMAJ. 2009;188(10):E47-E57
9 PRECIS Tool - Examples Thorpe. CMAJ. 2009;188(10):E47-E57
10 Part II: Observational Studies
11 Observational Studies Subject not randomized Treatments/exposure delivered in natural settings Cohort studies identify exposure; then outcome(s) Retrospective cross-sectional or longitudinal All data collected before commencement of study Prospective typically longitudinal Consequential outcomes data collected after commencement of study Case-control studies identify outcome; then exposure(s) Always retrospective - longitudinal
12 Advantages of observational studies Useful for characterizing a population Useful in CER/PCOR Avoids voluntary participation Generalizable to target population; often not the case in RCTs Faster and cheaper Data collected as part of larger surveillance goals Usually does not require expensive protocol
13 Disadvantages of observational studies Study design Treatments, exclusion/inclusion criteria/follow-up period etc. determined by the data at hand Outcomes All relevant outcomes may not be available Causal Inference eliminating bias Must deal with confounders Requires use of more advanced statistical techniques
14 A word about validity RCTs often produce internally valid estimates, but may not be externally valid (generalizable) Internal validity is NECESSARY but NOT SUFFICIENT for external validity. Observational studies cannot provide externally valid estimates if they are not internally valid.
15 Good Practice Recommendations CER (with observational data) only relevant when there is clinical equipoise In presence of strong treatment preferences it is difficult to control for confounding or bias Retrospective data are most useful here Specify hypothesis, up front Specify population, comparators, outcomes of interest
16 Good Practice Recommendations Specify study design Strongest design always includes a control group Cohort pre/post Good to assess one or more outcomes Can assess one or more exposures Case-control Good to assess rare outcome (usually one) Can assess many exposures Case-Crossover Designs Individuals serve as their own controls Case-Time-Control Designs Case-crossover design with external control group to control for temporal trends
17 Good Practice Recommendations Two types of bias Observed can address by including covariates or stratification Unobserved requires advanced techniques Address presence of treatment effect heterogeneity Issues in estimation sample size etc. Issues in interpretability of results level of aggregation Issues in generalizability what does the mean effect tell us What are the moderators of treatment effect mostly use baseline characteristics
18 Good Practice Recommendations Observational data invaluable source of data for CER Clear descriptions of hypothesis, study design and methods are important for a good observational CER study Confounding is main issue Often advanced statistical methods are needed to address confounding
19 ISPE Guidelines for Good Pharmacoepidemiology Practices (GPP). References Gliklich R, Dreyer N, Leavy M, eds. Registries for Evaluating Patient Outcomes: A User s Guide. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guideline. REporting of studies Conducted using Observational Routinely-collected Data (RECORD). ISPOR, Good Pharmacoepidemiology Practices, ISPOR Good Research Practices for Observational Data (many) European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Luce BR et al. Principles for planning and conducting comparative effectiveness research. Journal of Comparative Effectiveness Research 2012; 1(5):
20 Case Study I: Prospective Cohort CER Study of Intermittent Claudication (IC): Impact of Intervention Type on Patient Function and Health-Related Quality of Life Devine Alfonso-Cristancho Yanez, Edwards Patrick, Armstrong Devlin, Symons, Thomason, Meissner, Clowes, Lavallee, Kessler, Flum, and CERTAIN Collaborative Funded by AHRQ R01HS (PI: Flum)
21 Patient Voices Clinician Offices Hospitals Long-term Care Facilities Clinical Practice Partners Evidence Generation Dissemination & Implementation
22 IC Study Methods Study Design: Multisite, longitudinal, prospective, observational cohort study conducted from Aims: Compare baseline, 6 & 12 month functional, health-related quality of life and symptoms among subjects receiving medical management vs. surgical or endovascular procedures for treatment of intermittent claudication Hypothesis: At 12-months, surgical and endovascular procedures are associated with greater improvements in function, health-related quality of life, and symptoms than the medical management cohort
23 Lessons Learned from the IC Study Patient reported outcome (PRO) measures can be used as primary and secondary outcomes Recruitment efforts are often Intense Always adjust analyses for baseline characteristics Data collected from both electronic health records and directly from patients provides the opportunity to compare patient reported outcomes to clinically reported outcomes Engage a biostatistician to assist with study design, power calculations and analyses Infrastructure is expensive to build initially; once built, additional studies can be conducted for modest incremental investment
24 Case Study II: Retrospective Cohort Estimating the costs of atrial fibrillation and associated adverse events Forrester SH, Li M, Roth G, Devine EB
25 Atrial fibrillation (AF) study methods Study Design: Matched (1:4), retrospective cohort study of patients 18 years old with incident AF(ICD ) between 2008 and 2010 Aim: Estimate the incremental costs of events (ischemic stroke, myocardial infarction, systemic embolism, intracranial hemorrhage, or GI bleed) in patients with AF
26 Lessons Learned from the A fib Study Time invested in developing study design and protocol, a priori, is a must When using administrative claims data, clearly define run-in period; date of index diagnosis; date of intervention; define adequate follow-up period Illustrations are helpful in refining these design characteristics draw it out! Control for baseline characteristics and potential confounders Engage a biostatistician to assist with study design, power calculations and analyses
27 Thank You! Questions?
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research
Research in Real-World Settings: PCORI s Model for Comparative Clinical Effectiveness Research David Hickam, MD, MPH Director, Clinical Effectiveness & Decision Science Program April 10, 2017 Welcome!
More informationReal-world data in pragmatic trials
Real-world data in pragmatic trials Harold C. Sox,MD The Patient-Centered Outcomes Research Institute Washington, DC Presenter Disclosure Information In compliance with the accrediting board policies,
More informationA Framework for Patient-Centered Outcomes Research
A Framework for Patient-Centered Outcomes Research David H. Hickam, MD, MPH Director of Research Methodology, PCORI Baltimore, MD August 9, 2016 Session Faculty Disclosures David H. Hickam, MD, MPH No
More informationComparative Effectiveness Clinical Trials in the Elderly: Practical and Methodological Issues
Comparative Effectiveness Clinical Trials in the Elderly: Practical and Methodological Issues Peter Peduzzi, PhD Yale Center for Analytical Sciences Yale School of Public Health VA Cooperative Studies
More informationTopic 1: What Are Embedded Pragmatic Clinical Trials?
Topic 1: What Are Embedded Pragmatic Clinical Trials? Part 1: Lesley Curtis, PhD Director, Center for Pragmatic Health Systems Research Duke Clinical Research Institute Collaboratory epct Training Workshop
More informationPragmatic Clinical Trials. Disclosure/Conflict of Interest. Learning Objectives 7/15/2015. Friedly: No disclosures
Pragmatic Clinical Trials Jerry Jarvik M.D., M.P.H. Department of Radiology Janna Friedly M.D. Department of Rehabilitation Medicine Disclosure/Conflict of Interest Friedly: No disclosures Jarvik: HealthHelp
More informationPragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Christine Hunter Russ Glasgow
Pragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Christine Hunter Russ Glasgow Basic Idea The importance of an idea or action lies in whether it makes a difference in everyday
More informationAccelerating Patient-Centered Outcomes Research and Methodological Research
Accelerating Patient-Centered Outcomes Research and Methodological Research Jason Gerson, PhD CER Methods JSM 2016 July 31, 2016 In This Session PCORI Overview Methods Program Overview Methods Program
More informationDepartment of OUTCOMES RESEARCH
Department of OUTCOMES RESEARCH Clinical Research Design Sources of Error Types of Clinical Research Randomized Trials! Daniel I. Sessler, M.D. Professor and Chair Department of OUTCOMES RESEARCH The Cleveland
More informationResponding to the Spirit of 21 st Century Cures Legislation
Responding to the Spirit of 21 st Century Cures Legislation Clinical Research Forum Industry Forum September 25, 2017 Joe Selby, MD MPH Executive Director, PCORI For Today Doing Research Differently: Patient-Centered
More informationClinically Meaningful Inclusion of Participants in Clinical Trials. David Hickam, MD, MPH Washington, DC April 9, 2015
Clinically Meaningful Inclusion of Participants in Clinical Trials David Hickam, MD, MPH Washington, DC April 9, 2015 Key Questions for this Presentation What are the important features of patient centered
More informationAppraising the Literature Overview of Study Designs
Chapter 5 Appraising the Literature Overview of Study Designs Barbara M. Sullivan, PhD Department of Research, NUHS Jerrilyn A. Cambron, PhD, DC Department of Researach, NUHS EBP@NUHS Ch 5 - Overview of
More informationChoosing the right study design
Choosing the right study design Main types of study design Randomised controlled trial (RCT) Cohort study Case-control study Cross-sectional study Case series/case note review Expert opinion BEST QUALITY
More informationImproving reporting for observational studies: STROBE statement
Improving reporting for observational studies: STROBE statement Technical meeting on the reporting of human studies submitted for the scientific substantiation of health claims EFSA Parma 20 November 2013
More informationProtocol Development: The Guiding Light of Any Clinical Study
Protocol Development: The Guiding Light of Any Clinical Study Susan G. Fisher, Ph.D. Chair, Department of Clinical Sciences 1 Introduction Importance/ relevance/ gaps in knowledge Specific purpose of the
More informationCLINICAL REGISTRIES Use and Emerging Best Practices
CLINICAL REGISTRIES Use and Emerging Best Practices Tim Friede Department of Medical Statistics University Medical Center Göttingen DZHK (German Center for Cardiovascular Research) OUTLINE Background:
More informationAchieving Operational Excellence in Prospective Observational Research
Achieving Operational Excellence in Prospective Observational Research Louise Parmenter PhD, MSc VP, Global Head of Operations, Epidemiology & Outcomes Research Ombretta Palucci Senior Director, EMEA RWLP
More informationReport published in Trials, 2016, 17:32
Presented by Karin Johnson and Gila Neta On behalf of Laura M. Dember, Gloria D. Coronado, Jerry Suls, David A. Chambers, Sean Rundell, David H. Smith, Benmei Liu, Stephen Taplin, Catherine M. Stoney,
More informationStudy Designs in Epidemiology
Study Designs in Epidemiology Dr. Sireen Alkhaldi, BDS, MPH, DrPH First semester 2017/ 2018 Department of Family and Community Medicine School of Medicine/ The University of Jordan Epidemiologic Study
More informationModule 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town
Module 5 The Epidemiological Basis of Randomised Controlled Trials Landon Myer School of Public Health & Family Medicine, University of Cape Town Introduction The Randomised Controlled Trial (RCT) is the
More informationWelcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH
Pragmatic Clinical Studies David Hickam, MD, MPH Program Director Clinical Effec2veness Research June 23, 2015 Welcome! David Hickam, MD, MPH Program Director Clinical Effectiveness Research 2 In this
More informationEvidence- and Value-based Solutions for Health Care Clinical Improvement Consults, Content Development, Training & Seminars, Tools
Definition Key Points Key Problems Bias Choice Lack of Control Chance Observational Study Defined Epidemiological study in which observations are made, but investigators do not control the exposure or
More informationPragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Russ Glasgow
Pragmatic Trials and Comparative Effectiveness Research (CER) Sharon Straus Russ Glasgow Key Take Home Points Many similarities between pragmatic research and CER-T Stakeholder (and patient) perspective
More informationPresenter Disclosure Information
Presenter Disclosure Information Soko Setoguchi, MD DrPH Prescription Drug Data: Advantages, Availability, and Access FINANCIAL DISCLOSURE: Grants/Research Support: NIH, AHRQ UNLABELED/UNAPPROVED USES
More informationDeveloping a Protocol for Observational Comparative Effectiveness Research. A User s Guide
Developing a Protocol for Observational Comparative Effectiveness Research A User s Guide The Agency for Healthcare Research and Quality s (AHRQ) Effective Health Care Program conducts and supports research
More informationAlternative Approaches to Tuberculosis Treatment Evaluation: The Role of Pragmatic Trials
Alternative Approaches to Tuberculosis Treatment Evaluation: The Role of Pragmatic Trials Daniel Bratton MRC Clinical Trials Unit 5 th October 2011 Overview Definition of pragmatic and explanatory attitudes
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationVACCINE ACTIVE SURVEILLANCE I
VACCINE ACTIVE SURVEILLANCE I Caitlin N Dodd, MS Biostatistician, Global Child Health Cincinnati Children s Hospital Medical Center CONTENTS M1 Compare epidemiological study methods Discuss the benefits
More informationOverview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools: Opportunities and Challenges of Application in Developing DRIs
Workshop on Guiding Principles for the Inclusion of Chronic Diseases Endpoints in Future Dietary Reference Intakes (DRIs) Overview and Comparisons of Risk of Bias and Strength of Evidence Assessment Tools:
More informationResearch Designs For Evaluating Disease Management Program Effectiveness
Research Designs For Evaluating Disease Management Program Effectiveness Disease Management Colloquium June 27-30, 2004 Ariel Linden, Dr.P.H., M.S. President, Linden Consulting Group 1 What s the Plan?
More informationGeneralizing the right question, which is?
Generalizing RCT results to broader populations IOM Workshop Washington, DC, April 25, 2013 Generalizing the right question, which is? Miguel A. Hernán Harvard School of Public Health Observational studies
More informationISPOR Good Research Practices for Retrospective Database Analysis Task Force
ISPOR Good Research Practices for Retrospective Database Analysis Task Force II. GOOD RESEARCH PRACTICES FOR COMPARATIVE EFFECTIVENESS RESEARCH: APPROACHES TO MITIGATE BIAS AND CONFOUNDING IN THE DESIGN
More informationPRECIS Guidance and Pragmatic Clinical Trials. Ryan Bradley, ND, MPH Assistant Professor, Family Medicine and Public Health
PRECIS Guidance and Pragmatic Clinical Trials Ryan Bradley, ND, MPH Assistant Professor, Family Medicine and Public Health PRECIS PRagmatic-Explanatory Continuum Indicator Summary (PRECIS) PRECIS= a summary
More informationUsing the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview
Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview Millions of people. Strong collaborations. Privacy first. Jeffrey Brown,
More informationAdvancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development
Advancing Molecular Diagnostics for Oncology: Partnerships to Accelerate Evidence Development Assessing Clinical Utility with Real-World Evidence IOM/CMTP Workshop May 2012 G. Rossi Ph.D. V.P. Payer and
More informationObservational Study Designs. Review. Today. Measures of disease occurrence. Cohort Studies
Observational Study Designs Denise Boudreau, PhD Center for Health Studies Group Health Cooperative Today Review cohort studies Case-control studies Design Identifying cases and controls Measuring exposure
More informationDeclaration of interests. Register-based research on safety and effectiveness opportunities and challenges 08/04/2018
Register-based research on safety and effectiveness opportunities and challenges Morten Andersen Department of Drug Design And Pharmacology Declaration of interests Participate(d) in research projects
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Thank you for agreeing to give us a statement on your organisation s view of the technology and the way
More informationHandout 1: Introduction to the Research Process and Study Design STAT 335 Fall 2016
DESIGNING OBSERVATIONAL STUDIES As we have discussed, for the purpose of establishing cause-and-effect relationships, observational studies have a distinct disadvantage in comparison to randomized comparative
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationBiases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University
Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of
More informationOBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP
OBSERVATIONAL Patient-centered observational analytics: New directions toward studying the effects of medical products Patrick Ryan on behalf of OMOP Research Team May 22, 2012 Observational Medical Outcomes
More informationISPOR Task Force Report: ITC & NMA Study Questionnaire
INDIRECT TREATMENT COMPARISON / NETWORK META-ANALYSIS STUDY QUESTIONNAIRE TO ASSESS RELEVANCE AND CREDIBILITY TO INFORM HEALTHCARE DECISION-MAKING: AN ISPOR-AMCP-NPC GOOD PRACTICE TASK FORCE REPORT DRAFT
More informationClinical Evidence: Asking the Question and Understanding the Answer. Keeping Up to Date. Keeping Up to Date
Clinical Evidence: Asking the Question and Understanding the Answer Keeping Up to Date 5,000? per day 1,500 per day 95 per day Keeping Up to Date 5,000? per day 1,500 per day 95 per day 1 Bias Bias refers
More informationIMPACT OF INCLUSION/ EXCLUSION CRITERIA ON ENROLLMENT
2014 CTN Web Seminar Series IMPACT OF INCLUSION/ EXCLUSION CRITERIA ON ENROLLMENT Presented by: Robert Lindblad, MD & Gaurav Sharma, PhD NIDA Clinical Coordinating & Data and Statistics Centers The EMMES
More informationGlossary of Practical Epidemiology Concepts
Glossary of Practical Epidemiology Concepts - 2009 Adapted from the McMaster EBCP Workshop 2003, McMaster University, Hamilton, Ont. Note that open access to the much of the materials used in the Epi-546
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationPlans for Surveillance of Acute Myocardial Infarction in users of Oral Anti Diabetes Drugs
Plans for Surveillance of Acute Myocardial Infarction in users of Oral Anti Diabetes Drugs Bruce Fireman Kaiser Permanente, Oakland Brookings, Washington DC, 1 12 2011 Aims Develop and assess a framework
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationMeeting Summary. May 12-13, 2011 Hyatt Regency Baltimore, Maryland
LARGE SIMPLE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH IN CHRONIC DISEASE WORKSHOP: MEDICARE DATA UNITED WITH SIMPLE CLINICAL EXPANDED NETWORK (MUSCLE) Meeting Summary May 12-13, 2011 Hyatt Regency
More informationPerspectives on Large Simple Trials
Perspectives on Large Simple Trials Michael S Lauer, MD, FACC, FAHA Director, Division of Cardiovascular Sciences NHLBI/NIH May 8, 2012 Disclosures: None financial; my views only Three Questions Why trials?
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationIntervention vs. Observational Trials:
Intervention vs. Observational Trials: A Brief Introduction Introduction Just like an architect translates a vision for a building into blueprints, so an investigator translates their research idea into
More informationFinding Research Questions: Look at Both the New and the Old. September 23, 2016 Josie Briggs MD NIA Aging Research for the Specialties
Finding Research Questions: Look at Both the New and the Old September 23, 2016 Josie Briggs MD NIA Aging Research for the Specialties Quirky Ideas From Outside the Mainstream Physical resistance training
More informationWashington, DC, November 9, 2009 Institute of Medicine
Holger Schünemann, MD, PhD Chair, Department of Clinical Epidemiology & Biostatistics Michael Gent Chair in Healthcare Research McMaster University, Hamilton, Canada Washington, DC, November 9, 2009 Institute
More informationobservational studies Descriptive studies
form one stage within this broader sequence, which begins with laboratory studies using animal models, thence to human testing: Phase I: The new drug or treatment is tested in a small group of people for
More informationTrial clinici nell anziano: efficacy or effectiveness?
LA SPERIMENTAZIONE FARMACOLOGICA CLINICA IN ETÀ GERIATRICA Trial clinici nell anziano: efficacy or effectiveness? Graziano Onder Fondazione Universitaria Policlinico A. Gemelli Università Cattolica del
More informationPredicting Aneurysm Rupture
Predicting Aneurysm Rupture Robert E. Harbaugh, MD, FAANS, FACS, FAHA Director, Penn State Institute of the Neurosciences University Distinguished Professor & Chair, Department of Neurosurgery Professor,
More informationBeyond the intention-to treat effect: Per-protocol effects in randomized trials
Beyond the intention-to treat effect: Per-protocol effects in randomized trials Miguel Hernán DEPARTMENTS OF EPIDEMIOLOGY AND BIOSTATISTICS Intention-to-treat analysis (estimator) estimates intention-to-treat
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationCausal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra
Causal Inference Framework for Considering the Cardiovascular Risks Associated with Ortho Evra B. Burt Gerstman June 2008 This brief document addresses the question Does Ortho Evra cause more cardiovascular
More informationOverview of Study Designs in Clinical Research
Overview of Study Designs in Clinical Research Systematic Reviews (SR), Meta-Analysis Best Evidence / Evidence Guidelines + Evidence Summaries Randomized, controlled trials (RCT) Clinical trials, Cohort
More informationImplementation Science: Evidence to Action. Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University
Implementation Science: Evidence to Action Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline Achievements and challenges in HIV response Knowledge-impact gap (Know-do gap) Research pathway
More informationBritish Geriatrics Society
Healthcare professional group/clinical specialist statement Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationPragmatic Phase III Trials. Maria Koehler MD PhD Pfizer Oncology Strategy and Innovation NY, NY
Pragmatic Phase III Trials Maria Koehler MD PhD Pfizer Oncology Strategy and Innovation NY, NY DISCLOSURE I am an employee of Pfizer Inc, USA Current Randomized Clinical Trials Standard for regulatory
More informationPopulation based studies in Pancreatic Diseases. Satish Munigala
Population based studies in Pancreatic Diseases Satish Munigala 1 Definition Population-based studies aim to answer research questions for defined populations 1 Generalizable to the whole population addressed
More informationQuality & Observational Studies
Quality & Observational Studies Sara Montanari Responsible Quality Assurance MediData srl GIQAR 2015, Napoli The aim of QUALITY MANAGEMENT in clinical research is: i. To avoid bias of results by using
More informationRobert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration
Robert Temple, MD Deputy Center Director for Clinical Science Center for Drug Evaluation and Research Food and Drug Administration USE OF REAL WORLD DATA ( BIG DATA ) FOR REGULATORY PURPOSES ISCTM Meeting
More informationStatistics for Clinical Trials: Basics of Phase III Trial Design
Statistics for Clinical Trials: Basics of Phase III Trial Design Gary M. Clark, Ph.D. Vice President Biostatistics & Data Management Array BioPharma Inc. Boulder, Colorado USA NCIC Clinical Trials Group
More informationEpidemiologic Methods I & II Epidem 201AB Winter & Spring 2002
DETAILED COURSE OUTLINE Epidemiologic Methods I & II Epidem 201AB Winter & Spring 2002 Hal Morgenstern, Ph.D. Department of Epidemiology UCLA School of Public Health Page 1 I. THE NATURE OF EPIDEMIOLOGIC
More information115 remained abstinent. 140 remained abstinent. Relapsed Remained abstinent Total
Chapter 10 Exercises 1. Intent-to-treat analysis: Example 1 In a randomized controlled trial to determine whether the nicotine patch reduces the risk of relapse among smokers who have committed to quit,
More informationIncorporating Clinical Information into the Label
ECC Population Health Group LLC expertise-driven consulting in global maternal-child health & pharmacoepidemiology Incorporating Clinical Information into the Label Labels without Categories: A Workshop
More informationPropensity scores and instrumental variables to control for confounding. ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD
Propensity scores and instrumental variables to control for confounding ISPE mid-year meeting München, 2013 Rolf H.H. Groenwold, MD, PhD WP2 WG2: aims Evaluate methods to control for observed and unobserved
More informationUpdates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course
Updates in Therapeutics 2015: The Pharmacotherapy Preparatory Review & Recertification Course Study Designs: Fundamentals and Interpretation Kevin M. Sowinski, Pharm.D., FCCP Purdue University, College
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationThe Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved
The Academy Capitol Forum: Meet the Experts Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved Presenter: Gregory Martin, Deputy Directory of Stakeholder Engagement
More informationN of 1 trials: planning, conduct, and evaluation
N of 1 trials: planning, conduct, and evaluation Sunita Vohra MD MSc FRCPC FCAHS Director, CARE Program Director, Integrative Health Institute Centennial Professor, Dept. of Pediatrics Faculty of Medicine
More informationUNDERSTANDING EPIDEMIOLOGICAL STUDIES. Csaba P Kovesdy, MD FASN Salem VA Medical Center, Salem VA University of Virginia, Charlottesville VA
UNDERSTANDING EPIDEMIOLOGICAL STUDIES Csaba P Kovesdy, MD FASN Salem VA Medical Center, Salem VA University of Virginia, Charlottesville VA Study design in epidemiological research: Summary Observational
More informationEffective Health Care
Number 3 Effective Health Care Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Executive Summary Background Anemia (deficiency of red blood
More informationObjectives. Comparative Effectiveness Research: What is it and How is it Relevant to Pharmacy? How much do you know about CER? Glen T.
Comparative Effectiveness Research: What is it and How is it Relevant to Pharmacy? Glen T. Schumock Illinois Council of Health-System Pharmacists 2011 Annual Meeting, September 17 2011 The speaker has
More informationIs There An Association?
Is There An Association? Exposure (Risk Factor) Outcome Exposures Risk factors Preventive measures Management strategy Independent variables Outcomes Dependent variable Disease occurrence Lack of exercise
More informationIn this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials
In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials are comparative, large scale studies that typically
More informationExperimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial
Experimental Design Chusak Okascharoen, MD, PhD September 19 th, 2016 Terminology Experimental study Clinical trial Randomized controlled trial 1 PHASES OF CLINICAL TRIALS Phase I: First-time-in-man studies
More informationThe Trauma Survivors Outcomes & Support (TSOS) Pragmatic Trial Targeting PTSD and Comorbidity: Design and Early Implementation
The Trauma Survivors Outcomes & Support (TSOS) Pragmatic Trial Targeting PTSD and Comorbidity: Design and Early Implementation Douglas Zatzick, MD Professor Department of Psychiatry & Doyanne Darnell,
More informationFIRST DO NO HARM: AN EBM ODYSSEY. Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC
FIRST DO NO HARM: AN EBM ODYSSEY Cathleen Colón-Emeric, MD, MHS Geriatrics, Department of Medicine Durham VA GRECC colon001@mc.duke.edu 919 660-7517 Learning Objectives 1. Describe the types of studies
More informationAuthors Introduction to Pragmatic Trials. and Stepped Wedge Designs. Sandra Eldridge
Title 2 nd KCE TRIALS SYMPOSIUM 28 th November 2017 Authors Introduction to Pragmatic Trials Including Centre for Cluster Care & Randomised Public Health Trials Blizard Institute and Stepped Wedge Designs
More informationCAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL?
CAN EFFECTIVENESS BE MEASURED OUTSIDE A CLINICAL TRIAL? Mette Nørgaard, Professor, MD, PhD Department of Clinical Epidemiology Aarhus Universitety Hospital Aarhus, Denmark Danish Medical Birth Registry
More informationInternal Validity and Experimental Design
Internal Validity and Experimental Design February 18 1 / 24 Outline 1. Share examples from TESS 2. Talk about how to write experimental designs 3. Internal validity Why randomization works Threats to
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationIntroduction to the Patient- Centered Outcomes Research Institute
Introduction to the Patient- Centered Outcomes Research Institute Laura Forsythe, PhD, MPH Senior Program Officer, Research Integration and Evaluation 1 About PCORI pcori.org/about About PCORI An independent
More informationRandomized Controlled Trial
Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationHow to use PRECIS-2 - Designing trials that are fit for purpose
PRECIS-2 toolkit We would be very grateful if users would give us feedback on using PRECIS-2: just click on Contact us. These PRECIS-2 criteria are constantly being reviewed and we welcome your input.
More informationRegistry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency
More informationShared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA
Shared Decision Making in Diabetes: What, Why, and How? Nilay D. Shah Mayo Clinic Rochester, Minnesota, USA Disclosures Funding provided by: AHRQ: R18 HS019214; R18 HS018339 NIDDK: R34 DK84009 Foundation
More informationPractical Interventions for Co-occurring Disorders: Dissemination from Efficacy and Effectiveness Studies
Practical Interventions for Co-occurring Disorders: Dissemination from Efficacy and Effectiveness Studies Sitharthan Thiagarajan *Australian Centre for Addiction Research www.acar.net.au Today s presentation
More informationHow should clinical trials in brain injury be designed
How should clinical trials in brain injury be designed Alexis F. Turgeon MD MSc FRCPC Associate Professor and Director of Research Department of Anesthesiology and Critical Care Medicine Division of Critical
More information